Article
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
The New England journal of medicine - 29 Oct 2015
Tiacci Enrico, Park Jae H, De Carolis Luca, Chung Stephen S, Broccoli Alessandro, Scott Sasinya, Zaja Francesco, Devlin Sean, Pulsoni Alessandro, Chung Young R, Cimminiello Michele, Kim Eunhee, Rossi Davide, Stone Richard M, Motta Giovanna, Saven Alan, Varettoni Marzia, Altman Jessica K, Anastasia Antonella, Grever Michael R, Ambrosetti Achille, Rai Kanti R, Fraticelli Vincenzo, Lacouture Mario E, Carella Angelo M, Levine Ross L, Leoni Pietro, Rambaldi Alessandro, Falzetti Franca, Ascani Stefano, Capponi Monia, Martelli Maria P, Park Christopher Y, Pileri Stefano A, Rosen Neal, Foà Robin, Berger Michael F, Zinzani Pier L, Abdel-Wahab Omar, Falini Brunangelo, Tallman Martin S
Abstract excerpt
BACKGROUND: BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues. METHODS: We conducted two phase 2, single-group, multicenter studies of vemurafenib (at a dose of 960 mg twice...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.